European Journal of Internal Medicine
Volume 18, Issue 4 , Pages 272-282, July 2007

Endothelins in health and disease

  • Rahman Shah

      Affiliations

    • Corresponding Author InformationTel.: +1 617 525 6733; fax: +1 617 582 6027.

Section of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA

Received 26 August 2006; received in revised form 3 January 2007

Abstract 

Endothelins are powerful vasoconstrictor peptides that also play numerous other roles. The endothelin (ET) family consists of three peptides produced by a variety of tissues. Endothelin-1 (ET-1) is the principal isoform produced by the endothelium in the human cardiovascular system, and it exerts its actions through binding to specific receptors, the so-called type A (ETA) and type B (ETB) receptors. ET-1 is primarily a locally acting paracrine substance that appears to contribute to the maintenance of basal vascular tone. It is also activated in several diseases, including congestive heart failure, arterial hypertension, atherosclerosis, endothelial dysfunction, coronary artery diseases, renal failure, cerebrovascular disease, pulmonary arterial hypertension, and sepsis. Thus, ET-1 antagonists are promising new agents. They have been shown to be effective in the management of primary pulmonary hypertension, but disappointing in heart failure. Clinical trials are needed to determine whether manipulation of the ET system will be beneficial in other diseases.

Keywords: Endothelins, Vasoconstriction, Vasoactive agents

 

PII: S0953-6205(07)00087-8

doi:10.1016/j.ejim.2007.04.002

European Journal of Internal Medicine
Volume 18, Issue 4 , Pages 272-282, July 2007